Menu

Life Sciences Search Engine

A startup aims to make doing research easier by mining publications for research products, protocols, and potential collaborators.

Jul 22, 2016
Alison F. Takemura

FLICKR, U.S. ARMY MATERIEL COMMANDA good reagent can be hard to find. It typically takes wading through journal articles and published protocols to determine how best to set up an experiment. But a new search engine, Bioz, is hoping to streamline that process. The Palo Alto startup this week (June 20) announced $3 million in seed funding to improve their venture, which is currently in beta.

The site works by using natural language processing and machine learning to mine papers for a treasure-trove of information. A user can enter in a method (“PCR”) or a tool (“DNA polymerase”) and Bioz identifies reagents, ranking them according to how many times they’ve been used in experiments, the impact factor of the journal in which the referenced papers were published, and how recently a product was used.

Each result links to the vendor’s webpage. Bioz receives a lead referral fee, making the service free for users.

In addition, the search engine suggests relevant assays and collaborators, and shows the article context that describes how certain reagents were used.

Founder Karin Lachmi of Stanford explained the value of this feature: “Ok, I know what experiment I’m trying to do and I know the product, but now I want to go further,” she told Bio-IT World. “Should I use it at room temperature? Should I use a 1:1,000 dilution or a 1:200 dilution?”

More than 11,000 people across 40 countries are now using the search engine. “The business model for Bioz is around things you can buy, but there’s a subtext that you should be paying attention to everything,” Esther Dyson, who has invested in the company, told Tech Crunch. “And Bioz can help you find all those external factors you may not be noticing.”

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.